Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo doubles down on next-gen weight loss therapy despite early setback
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
devdiscourse13d
Novo Nordisk's Bold Bet: CagriSema's Next Chapter in Obesity Treatment
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
NBC 10 Philadelphia13d
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Both Novo Nordisk and Eli Lilly's current weight loss treatments are administered via injection ... including its hotly anticipated experimental CagriSema treatment. Late-stage CagriSema trial ...
This is Money13d
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Revenues from weight loss injection medication Wegovy more ... drug CagriSema had fallen short of predictions. Novo Nordisk had forecast CagriSema leading to patients losing a quarter of their ...